TECregen raises €10.7M Seed round
8 January 2026· Basel, Switzerland· health, pharma, biotech, b2b, deep_hardware
The investment will be used to accelerate the development of TECregen's thymopoietic biologics designed to rejuvenate thymic epithelial cells, restore immune function, and reach the stage of nominating a lead candidate.
Investors
LeadBoehringer Ingelheim Venture Fund
Also participating
High-Tech GründerfondsCarma FundZurich Cantonal BankLifeSpan Vision VenturesEOS BioInnovationJFG Life Sciences Foundation of the University of Basel
About TECregen
Stage
Seed
Headquarters
Basel, Switzerland
Founded
2023
Team Size
6–20
Sectors
healthpharmabiotechb2bdeep_hardware